Basic Information
Ongentys
Regulatory Information
EMEA/H/C/002790
June 24, 2016
April 28, 2016
10
September 18, 2024
Company Information
Portugal
Av. da Siderurgia Nacional S. Mamede do Coronado 4745-457
BIAL - PORTELA & CA., S.A.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.Ongentys is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Ongentys. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ongentys. For practical information about using Ongentys, patients should read the package leaflet or contact their doctor or pharmacist.